(1R,9R,10S,12R,13S,14R,16S,18R)-13-ethyl-8-methyl-8,15-diazahexacyclo[14.2.1.0^{1,9}.0^{2,7}.0^{10,15}.0^{12,17}]nonadeca-2,4,6-triene-14,18-diol

• ChemBase编号: 1234
• 分子式: C20H26N2O2
• 平均质量: 326.43264
• 单一同位素质量: 326.19942808
• SMILES: c1ccc2c(c1)[C@@]13[C@@H](N2C)[C@H]2N4[C@@H](C1)C([C@@H](C2)[C@@H]([C@H]4O)CC)[C@H]3O
• Canonical SMILES: CC[C@H]1[C@@H]2C[C@@H]3N([C@@H]1O)[C@@H]1C2[C@@H](O)[C@]2([C@H]3N(C)c3c2cccc3)C1
• InChI: InChI=1S/C20H26N2O2/c1-3-10-11-8-14-17-20(12-6-4-5-7-13(12)21(17)2)9-15(16(11)18(20)23)22(14)19(10)24/h4-7,10-11,14-19,23-24H,3,8-9H2,1-2H3/t10-,11-,14-,15-,16?,17-,18+,19+,20+/m0/s1
• InChIKey: CJDRUOGAGYHKKD-HEFSZTOGSA-N

名称和登记号

名称

• IUPAC标准名: (1R,9R,10S,12R,13S,14R,16S,18R)-13-ethyl-8-methyl-8,15-diazahexacyclo[14.2.1.0^{1,9}.0^{2,7}.0^{10,15}.0^{12,17}]nonadeca-2,4,6-triene-14,18-diol
• IUPAC传统名: ajmaline
• 别名: Ajmalin; Ajmaline

登记号

• CAS号: 4360-12-7
• PubChem SID: 160964694
• PubChem CID: 441080

理论计算性质

JChem

• Acid pKa: 13.280155
• 质子受体: 4
• 质子供体: 2
• LogD (pH = 5.5): 0.1535305
• LogD (pH = 7.4): 1.6402448
• Log P: 1.8508078
• 摩尔折射率: 92.5658 cm^3
• 极化性: 36.288525 Å^3
• 极化表面积: 46.94 Å^2
• 可自由旋转的化学键: 1
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 1.72
• LOG S: -1.9
• 溶解度: 4.09e+00 g/l

分子性质

理化性质

• 疏水性(logP): 1.81 [HANSCH,C ET AL. (1995)]

详细说明

DrugBank - DB01426

• Drug Groups: approved
• Description: An alkaloid found in the root of Rauwolfia serpentina, among other plant sources. It is a class Ia antiarrhythmic agent that apparently acts by changing the shape and threshold of cardiac action potentials. Ajmaline produces potent sodium channel blocking effects and a very short half-life which makes it a very useful drug for acute intravenous treatments. The drug has been very popular in some countries for the treatment of atrial fibrillation in patients with the Wolff–Parkinson–White syndrome and in well tolerated monomorphic ventricular tachycardias. It has also been used for many years as a drug to challenge the conduction system of the heart in cases of bundle branch block and syncope. In these cases, abnormal prolongation of the HV interval has been taken as a proof for infrahisian conduction defects tributary for permanent pacemaker implantation.
• Indication: For use as an antiarrhythmic agent.
• Pharmacology: Ajmaline is a class 1A antiarrhythmic agent. By interfering with the sodium channels, this drug allows for improvement in abnormal rhythms of the heart
• Affected Organisms: Humans and other mammals
• References: Brugada J, Brugada P, Brugada R: The ajmaline challenge in Brugada syndrome: a useful tool or misleading information? Eur Heart J. 2003 Jun;24(12):1085-6. [Pubmed]
• External Links: Wikipedia

参考文献

• Brugada J, Brugada P, Brugada R: The ajmaline challenge in Brugada syndrome: a useful tool or misleading information? Eur Heart J. 2003 Jun;24(12):1085-6. Pubmed